Many cannabis companies are thinking about creative ways to pivot into the developing psychedelics market. One of the questions I hear most frequently hear is whether this is a good idea. It’s one thing for companies to leave cannabis altogether and go full tilt into the psychedelics space. But mixing cannabis and psychedelics into one
Over the last few months, I’ve written a few posts about SB-519, a bill introduced by California State Senator Scott Wiener earlier this year that is intended to decriminalize a host of psychedelics – from psilocybin to ketamine to LSD (you can read those posts here, here, and here). SB-519 has passed through the California
We’ve written a lot recently about the law concerning the religious use of psychedelics (see here and here). This is an incredibly broad area of the law that is still developing. Our focus has generally been on the federal laws and decisions affecting religious use of psychedelics, though today we turn our attention to an
Oregon is not the only jurisdiction with psilocybin (and other controlled psychedelic plant substances) on the ballot this fall. For our coverage of Oregon’s Measure 109, see: Oregon 2020 Election: Vote Yes! on Measure 109 Oregon and Psilocybin: Does the Approved Ballot Measure Language Stand a Chance? Oregon Psychedelics: Petition to Legalize Psilocybin for Therapy
I recently wrote a post outlining the long history of religious exemptions to the federal Controlled Substances Act (CSA). In this post, I’ll provide a brief overview of the hoops that religious organizations have to jump through. Religious organizations that want to use psychedelics for religious purposes and comply with U.S. law are forced to
On June 29, the folks at “Yes On IP 34” announced that the Psilocybin Therapy Initiative will qualify for the ballot this November in Oregon. The campaign said it had collected over 164,000 signatures and that its recent submission of additional signatures would comfortably put the initiative above the requirements. This is exciting news! You
Back in August, I covered the landmark Food and Drug Administration (FDA) drug trial approval for psilocybin, the naturally occurring, psychedelic ingredient found in around 200 species of mushrooms. I speculated that if everything goes well, we could see an approved psilocybin drug hit the market sometime in the next 5 to 10 years. I
